Phase 1 N=39 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
Ebola Virus
Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Phase 1 N=513 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
Phase 1 N=75 Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1
Influenza A Subtype H5N1 Infection
Primary: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose — 0; 0; 0; 0 Participants
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Phase 3 N=80 A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)
Hepatitis A Virus Infection
Primary: Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration…
Phase 3 N=1,332 Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
Tetanus · Acellular Pertussis · Diphtheria
Primary: Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value — 729; 374; 836; 428 subjects
Phase 1 N=40 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Phase 2 N=375 A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
Infections, Rotavirus · Rotavirus Vaccines
Primary: Number of Seroconverted Subjects for Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibody — 84 Subjects
Phase 2 N=140 Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
Genotype 1 Chronic Hepatitis C
Primary: EVR (Early Virologic Response) — 79.4; 78.5 percentage of participants — p=1.000
Phase 3 N=3,689 VELOCITY: An Anthrax Vaccine Clinical Study
Anthrax
Primary: Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64 — 0.765; 0.741; 0.716; 0.330 Titer (TNA NF50)
Early Phase 1 N=172 Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
Cognitive Side Effects of Cancer Therapy · Depression · Recurrent Breast Carcinoma
Primary: AUC Change in Level of IL-6 — 5.23; 10.17 ug*hour/ml
Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…
Phase 2 N=176 Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
Staphylococcus Aureus
Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events
Phase 3 N=300 A Safety and Immunogenicity Study of IVACFLU-A/H5N1
Avian Influenza
Primary: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40 — 0; 0; 0; 0 Participants
Phase 3 N=12,794 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
Phase 3 N=368 A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
Herpes Zoster
Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination — 717.5; 844.9 gpELISA units/mL
Phase 1 N=185 Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 4 N=3,032 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Smallpox Vaccine Adverse Reaction
Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants
N/A N=148 Healthy, Immunized Communities Study
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Phase 1 N=39 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Phase 1 N=61 Combination HTNV and PUUV DNA Vaccine
Hantaan Virus Disease, Puumala Virus
Primary: Summary of Solicited Local Adverse Events (AEs) — 8; 11; 12; 9 Participants
Phase 3 N=1,054 A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
Papillomavirus Infections
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 1637.9; 1725.0; 1170.3; 1212.6 milli Merck…
Phase 1 N=150 Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Human Papilloma Virus · Cervical Cancer · Vulvar Cancer
Primary: Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A — 1273.3; 2203.0; 4784.7; 1991.6 mMU/mL
Phase 1 N=114 Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
Covid19
Primary: Rate of Local Solicited Adverse Events After Each Study Vaccination — 13; 17; 11; 23 Participants
Phase 2 N=115 VSV-ZEBOV Geneva Vaccine Trial
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Phase 4 N=48 VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
Chronic Heart Failure
Primary: Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens — 11; 12 Participants — p=0.89
Phase 1 N=4 Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
Ricin Poisoning
Primary: Number of Vaccinated Participants Who Experienced Adverse Events by Nature and Severity. — 0; 3; 3; 2 participants